Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...
Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...
HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- ...
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...
The emergence of novel pharmacotherapies, minimally-invasive procedures and gene-directed approaches shall fundamentally alter the Hypertrophic Cardiomyopathy therapeutic landscape. Amongst all ...
The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...
Everyday Health on MSN
7 Ways to Manage Obstructive Hypertrophic Cardiomyopathy Symptoms
Obstructive hypertrophic cardiomyopathy comes with symptoms such as shortness of breath, fatigue, and palpitations. These tips can help you manage it.
For patients with hypertrophic cardiomyopathy that doesn’t improve with standard therapy, surgery may be the next choice. In France, a new study was conducted to compare the incidence of in-hospital ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...
In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results